YOUR COMPOUND / YOUR QUESTIONS

Semaglutide.

Semaglutide activates GLP-1 receptors, helping regulate appetite, food intake and blood glucose. Prescription products have evidence for weight management or type 2 diabetes, with additional benefits tied to specific indications; practitioners also discuss how to balance response, nutrition and tolerability.

Research focus: Appetite, body weight and blood-glucose control.

Randomized trials & product labelingSources checked October 12, 2026
View all compounds →

Choose a compound to open its research, documentation and calculator.

QUICK REFERENCE

The essentials.

Checked October 15, 2026
FDA status
FDA status and scope

Wegovy, Ozempic and Rybelsus: product- and indication-specific approval.

Official source ↗
FDA-approved products
Half-life
Half-life: source and route

Elimination half-life. This is not a storage window or a missed-dose rule.

Half-life describes concentration falling by half. It does not set a dosing interval, a storage period or a drug-test detection window.

Kinetics source ↗
About 7 daysHuman · product label
Diluent / formulation
Diluent and formulation

Approved injections are supplied as solutions; do not add diluent. Tablets are not mixed. A separately supplied powder requires its own formulation documentation.

Bacteriostatic water contains a preservative; plain sterile water does not. Preservative presence does not by itself establish compatibility or a mixed medicine’s usable period.

Preparation source ↗
Ready-to-use approved productsProduct labels
START WITH THE EVIDENCE

What the documentation tells us.

Evidence context

The label instructions below apply to the named prescription products and their indications. A matching peptide name on another vial does not establish an equivalent formulation.

Check that a source concerns the same molecule, formulation, route and population. A study of cells, animals or a different product cannot confirm the contents of a vial.

Randomized human trials and product-specific US labels; provider perspectives are identified separately.

Learn to read a study →
DOSAGE & SCHEDULE CONTEXT

Community schedules and research routes.

Dosage & schedule options.

Reading these schedules

Each entry keeps one schedule’s amount, frequency and cycle together. Community references, individual reports, clinical trials and prescription products describe different kinds of use. A missing duration or break stays marked as not reported.

Amounts describe mass in mg or mcg. Syringe units describe volume and depend on concentration. A cycle break is different from days off within a week.

Choose an option to explore its amounts, timing and cycle.

Prescription productWegovy injection · adult weight managementSubcutaneous16-week escalation, then ongoing maintenance

Dose
0.25 mg initially; usual maintenance 2.4 mg
How often
Once weekly throughout titration
Route
Subcutaneous
Duration
16-week escalation, then ongoing maintenance
Break after cycle
No scheduled cycle break in the label
Dose changes within this protocol
WhenAmount & frequency
Weeks 1–40.25 mg once weekly
Weeks 5–80.5 mg once weekly
Weeks 9–121 mg once weekly
Weeks 13–161.7 mg once weekly
Week 17 onward1.7 or 2.4 mg once weekly; 2.4 mg preferred

The label also permits 7.2 mg for selected adults after ≥4 weeks tolerating 2.4 mg when further weight reduction is indicated. Other indications have their own maintenance instructions.

Prescription productOzempic injection · adult type 2 diabetesSubcutaneous4-week starter stage; ongoing treatment thereafter

Dose
0.25 mg initially; maintenance 0.5, 1 or 2 mg
How often
Once weekly
Route
Subcutaneous
Duration
4-week starter stage; ongoing treatment thereafter
Break after cycle
No scheduled cycle break in the label
Dose changes within this protocol
WhenAmount & frequency
Weeks 1–40.25 mg once weekly
Week 5 onward0.5 mg once weekly
If additional glucose control is needed1 mg after ≥4 weeks at 0.5 mg; then 2 mg after ≥4 weeks at 1 mg

For type 2 diabetes with chronic kidney disease, see the label’s 1 mg maintenance schedule.

Prescription productRybelsus tablets · adult type 2 diabetesOral tablet30-day starter stage; ongoing treatment thereafter

Dose
3 mg initially; maintenance 7 or 14 mg
How often
Once daily
Route
Oral tablet
Duration
30-day starter stage; ongoing treatment thereafter
Break after cycle
No scheduled cycle break in the label
Time of day
Morning, empty stomach; ≤4 oz water; wait ≥30 minutes before food, drink or other oral medicines
Dose changes within this protocol
WhenAmount & frequency
Days 1–303 mg once daily
Days 31–607 mg once daily
Day 61 onward7 mg, or 14 mg if more glucose control is needed

Prescription productWegovy tablets · adult weight managementOral tablet90-day escalation, then ongoing maintenance

Dose
1.5 mg initially; maintenance 25 mg
How often
Once daily
Route
Oral tablet
Duration
90-day escalation, then ongoing maintenance
Break after cycle
No scheduled cycle break in the label
Time of day
Morning, empty stomach; ≤4 oz water; wait ≥30 minutes before food, drink or other oral medicines
Dose changes within this protocol
WhenAmount & frequency
Days 1–301.5 mg once daily
Days 31–604 mg once daily
Days 61–909 mg once daily
Day 91 onward25 mg once daily

Prescription productOzempic tablets · adult type 2 diabetesOral tablet30-day starter stage; ongoing treatment thereafter

Dose
1.5 mg initially; maintenance 4 or 9 mg
How often
Once daily
Route
Oral tablet
Duration
30-day starter stage; ongoing treatment thereafter
Break after cycle
No scheduled cycle break in the label
Time of day
Morning, empty stomach; ≤4 oz water; wait ≥30 minutes before food, drink or other oral medicines
Dose changes within this protocol
WhenAmount & frequency
Days 1–301.5 mg once daily
Days 31–604 mg once daily
Day 61 onward4 mg, or 9 mg if more glucose control is needed

Rybelsus and Ozempic tablets are not interchangeable milligram-for-milligram.

Individual community reportSlower weekly increases · reported useInjected; injection type not reported27 weeks of use reported

Dose
0.25 → 0.35 → 0.4 mg per injection
How often
Once/week
Route
Injected; injection type not reported
Duration
27 weeks of use reported
Break after cycle
Not reported
Dose changes within this protocol
WhenAmount & frequency
Initial weekly injections0.25 mg per injection
From injection 60.35 mg per injection
From injection 100.4 mg per injection

An individual account of extended lower amounts, separate from the product-specific schedules above.

Reconstitution & storage ↓
FROM THE COMMUNITY / WITH THE CONTEXT

Community research & perspectives.

About community labels

Community identifies source origin. It does not certify independent funding, medical credentials or the strength of a claim. Source types distinguish published reports, professional explanations and public discussions.

Explore reports, explanations and discussions from medical practices, researchers, suppliers and community members. The badges identify the source’s origin and evidence type.

How to read these source labels →
CommunityClinic explainer

Individual response and slower titration

Top Nutrition Coaching: evidence & source context

Not original trial data or a community survey. Its maximum-dose and missed-dose summaries do not capture all current product-label distinctions.

Source relationship: Markets GLP-1 prescribing and dietitian support.

A provider article discusses longer holds and prescriber follow-up. The guide compares this perspective with current product-specific instructions.

Provider explanation · commercial prescription and nutrition services

FORMULATION FIRST

Reconstitution, storage and devices.

Product-specific handling

A peptide name and vial mass cannot determine a compatible diluent, powder displacement, storage temperature or discard date. Follow the exact product’s instructions and your pharmacist’s directions.

The injection guide concerns clinician-prescribed subcutaneous medicines; it does not establish that a research-labeled material can be injected.

Start with the formulation: dry powder, prepared solution, pen, tablet and topical product can have different instructions.

Storage: before and after opening.

US product label

Wegovy · single-dose pen or syringe

Before opening
Refrigerate at 2–8°C (36–46°F), in the original carton.
After mixing / first use
If needed before cap removal: 8–30°C (46–86°F) for up to 28 days. Discard after use.
Handling & discard
Do not freeze. FlexTouch has separate in-use instructions; tablets are stored according to their bottle label.
Wegovy · storage section ↗
US product label

Ozempic · multi-dose pen

Before opening
Refrigerate at 2–8°C (36–46°F).
After mixing / first use
After first use: 56 days at 15–30°C (59–86°F) or refrigerated at 2–8°C.
Handling & discard
Do not freeze. Store without a needle attached, with the cap on. Prefilled syringes and tablets have different instructions.
Ozempic · storage section ↗

Compounded vials: match mg, mL and the syringe.

Why a vial needs its own instructions

Compounded products do not undergo FDA premarket review for safety, effectiveness or quality. FDA has reported measurement errors and hospitalizations involving compounded injectable semaglutide. Different concentrations, syringe markings and added ingredients prevent treating one vial’s instructions as universal.

A branded tablet or prefilled injection device is not a powder-vial preparation. For a prescribed compounded vial, have the dispensing pharmacy confirm the prescribed amount in mg, the concentration in mg/mL, the matching volume in mL and the markings on the supplied syringe.

On a U-100 syringe, 10 units means 0.1 mL. At 1 mg/mL that contains 0.1 mg; at 2.5 mg/mL it contains 0.25 mg. This illustrates why an online “units” chart cannot travel between concentrations. Storage and discard dates also belong to the dispensed formulation.

FDA’s dosing-error explanation ↗
THE EVERYDAY CONTEXT

Habits & tracking that help.

General health habits and consistent observations help you assess changes. They are not evidence that a peptide’s effects will be amplified.

Include movement and strength work

Choose activity that fits your health and ability. Aerobic movement and muscle-strengthening work are part of general adult activity guidance.

CDC · adult activity ↗

Keep a consistent sleep routine

Use a regular sleep/wake schedule and note changes in sleep quality alongside symptoms or training.

CDC · sleep habits ↗

What to record: Track food intake, appetite, activity and tolerability together. Appetite control should still leave room for adequate meals; review persistent eating difficulties with the treating clinician.

GO TO THE ORIGINAL

Documentation behind Semaglutide.

About source checks

Check dates are editorial references, not a medical review certificate. Labels and evidence can change; consult the linked current document.

Study details, timing & schedule comparisons

Same ingredient, different instructions.

Product safety and formulation context

Semaglutide labels carry a thyroid C-cell tumor boxed warning; the human risk is unknown. A personal or family history of medullary thyroid carcinoma, MEN 2, or serious semaglutide hypersensitivity are contraindications. Full labels also cover pancreatitis, severe gastrointestinal effects, dehydration and interactions with glucose-lowering medicines.

Full safety information ↗

Wegovy HD: for adult weight reduction, the label permits 7.2 mg weekly after at least four weeks tolerating 2.4 mg, if further reduction is clinically indicated. See indication-specific maintenance ↗

Tablet identity matters: Rybelsus and Ozempic tablets are not interchangeable milligram-for-milligram. Their starting doses are not effective for glucose control. The label specifies morning use on an empty stomach, with no more than four ounces of water, swallowing whole and waiting at least 30 minutes before food, drinks or other oral medicines. Read tablet administration instructions ↗

Kidney-disease indication: Ozempic injection’s type 2 diabetes with chronic kidney disease schedule uses 1 mg weekly after at least four weeks at 0.5 mg. Read indication-specific dosing ↗

Practitioner perspective · commercial provider

Gradual increases, with room for a clinical review.

Top Nutrition Coaching describes longer periods at lower amounts when results and side effects warrant it. The article credits dietitian Destini Moody and physician contributor Devon Allen. It offers a practical perspective, rather than original comparative trial data.

Wegovy’s injection label allows a four-week escalation delay for intolerance. Other changes need product-specific review. Appetite, adequate nutrition, glucose goals and unwanted effects are useful topics for that conversation; appetite suppression alone does not select a dose.

Read the provider’s perspective ↗Check the labeled delay ↗

Missed a dose? The product decides the rule.

Wegovy injection

Next dose more than 48 hours away: take the missed dose. Less than 48 hours: skip. Confirm boundary timing with a pharmacist. After two or more consecutive missed doses, contact the prescriber for lower-dose re-escalation.

Wegovy · §2.4 ↗

Ozempic injection

Take within five days of the missed dose; otherwise skip and resume on the scheduled day.

Ozempic · §2.1 ↗
THE MATH, EXPLAINED

Semaglutide calculator.

About calculator examples

Opening values and worked examples illustrate arithmetic; they are not preparation instructions or recommended amounts. Selecting a compound labels the calculation and does not supply a dose or powder-volume correction.

Enter the documented vial mass, preparation information and target amount to see how mass and volume connect.

An arithmetic example

20 mg in an assumed final 1 mL gives 20 mg/mL. An entered 1 mg corresponds to 0.05 mL, or 5 U-100 units, with 20 theoretical portions before losses.

YOUR CALCULATION WORKSPACE

Three tools. Clear numbers.

Open focused view →
01 / YOUR INPUTS

Vial → dose → syringe

mg
mL
Slider range: 1 to 20 mg, in 1 mg steps. Click a labeled value to select it. Type exact decimal amounts in the field above.
Advanced Volume & syringe settings
02 / YOUR RESULTCalculated

Semaglutide

Estimate · assumes 1 mL added = total volume

U-100 syringe1 mL capacity · 100 units
Amount per dose
1 mg

1,000 mcg

Full doses per vial
5

Theoretical · before losses

Syringe amount per dose
20units

0.2 mL

Amount remaining
0 mg

After 5 full doses

U-100 volume scale

Illustration only · calculated value, without rounding

Concentration & remaining liquid
Concentration
5 mg/mL
Per U-100 unit
50 mcg
Full portions in vial
5
Theoretical remainder
0 mL

Saved calculations stay on this device.

See the calculation

Concentration = mass ÷ final volume

5 mg ÷ 1 mL = 5 mg/mL

Volume = target mass ÷ concentration

1 mg ÷ 5 mg/mL = 0.2 mL

U-100 markings = volume × 100

0.2 mL × 100 = 20 units

Complete portions = floor(vial mass ÷ amount per portion).

Displayed numbers are rounded for readability; the calculation uses unrounded values.

Essential Always on

Remembers your privacy choice and any color theme you select. The calculator and research pages work with this alone.

Advertising Not used

Advertising personalization and Google signals are disabled.

Read the privacy & storage page →